Connor Clark & Lunn Investment Management Ltd. Has $918,000 Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 157.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 169,057 shares of the biopharmaceutical company's stock after buying an additional 103,495 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.28% of Sage Therapeutics worth $918,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Ieq Capital LLC bought a new stake in shares of Sage Therapeutics during the 4th quarter valued at $57,000. US Bancorp DE grew its stake in shares of Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock worth $67,000 after purchasing an additional 2,268 shares during the period. Empowered Funds LLC bought a new stake in Sage Therapeutics in the fourth quarter valued at about $91,000. SG Americas Securities LLC increased its holdings in Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 8,228 shares during the last quarter. Finally, Quest Partners LLC lifted its stake in Sage Therapeutics by 56.3% in the third quarter. Quest Partners LLC now owns 18,381 shares of the biopharmaceutical company's stock valued at $133,000 after buying an additional 6,618 shares during the period. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently issued reports on SAGE. Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Stifel Nicolaus lowered their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a "hold" rating for the company in a research report on Monday, December 16th. Wedbush reiterated a "neutral" rating and set a $6.00 target price on shares of Sage Therapeutics in a report on Wednesday, February 12th. Scotiabank dropped their price target on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group lowered their target price on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research note on Wednesday, February 12th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $8.81.

Remove Ads

Sage Therapeutics Price Performance

SAGE stock traded up $0.11 during mid-day trading on Monday, reaching $8.21. The company had a trading volume of 896,325 shares, compared to its average volume of 1,187,613. The company has a market capitalization of $504.76 million, a price-to-earnings ratio of -1.25 and a beta of 0.82. Sage Therapeutics, Inc. has a 52 week low of $4.62 and a 52 week high of $19.52. The stock has a 50 day simple moving average of $7.36 and a two-hundred day simple moving average of $6.70.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing the consensus estimate of ($1.54) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. On average, equities analysts predict that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.